Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04715620
Status:
UNKNOWN
Last Update Posted:
2021-01-20
First Post:
2021-01-13
Brief Title:
Niraparib Combined With Radiotherapy in rGBM
Sponsor:
Tianjin Huanhu Hospital
Organization:
Tianjin Huanhu Hospital
Study Overview
Official Title:
Efficacy and Safety of Niraparib Combined With Radiotherapy in Patients With Recurrent Glioblastoma
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Thirty patients were enrolled in this study mainly patients with first recurrence of glioblastoma and the requirement is that they can receive secondary radiotherapy Regardless of whether the patient has received a second operation or the MGMT promoter is methylated they can be included in this study After enrollment patients were given niraparib 300mgday body weight 77Kg and baseline platelet count 150000µL or 200mgday body weight 77Kg or baseline platelet count 150000µL combined with radiotherapy total dose 55Gy follow-up Time 1 year Until the patient has disease progression or intolerance or voluntarily withdraw from the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None